CAR T cell immunotherapy for human cancer

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509

Cancer regression in patients after transfer of genetically engineered lymphocytes

Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564

Adoptive cell transfer as personalized immunotherapy for human cancer

Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,545

T cell exclusion, immune privilege, and the tumor microenvironment

Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,539

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417

Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors

Laurent, P.-A., Morel, D., Meziani, L., Depil, S., & Deutsch, É. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2158013 · Cited by 34

Novel Immunotherapies for T Cell Lymphoma and Leukemia

Ghione, P., Moskowitz, A. J., Paola, N. D., Horwitz, S. M., & Ruella, M. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0480-8 · Cited by 34

CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them

Vanhooren, J., Dobbelaere, R., Derpoorter, C., Deneweth, L., Camp, L. V., Uyttebroeck, A., Moerloose, B. D., & Lammens, T. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000937 · Cited by 34

CRISPR applications in cancer diagnosis and treatment

Wang, M., Chen, M., Wu, X., Huang, X., & Yu, B. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00483-4 · Cited by 36

SCD1 inhibition enhances the effector functions of CD8 + T cells via ACAT1 ‐dependent reduction of esterified cholesterol

Sugi, T., Katoh, Y., Ikeda, T., Seta, D., Iwata, T., Nishio, H., Sugawara, M., Kato, D., Katoh, K., Kawana, K., et al. (2023) · Cancer Science · doi:10.1111/cas.15999 · Cited by 32

Anti-tumor immune potentiation targets-engineered nanobiotechnologies: Design principles and applications

Jiao, R., Lin, X., Zhang, Q., Zhang, Y., Qin, W., Yang, Q., Xu, C. S., Chen, F., & Zhang, K. (2023) · Progress in Materials Science · doi:10.1016/j.pmatsci.2023.101230 · Cited by 34

The Role of Cancer-Specific Target Antigens in CAR T Cell Therapy in Hematological Malignancies

Khan, T. H., Muhammad, N., Tarique, M., Usmani, D., Naz, H., & Sarode, A. Y. (2024) · Current Tissue Microenvironment Reports · doi:10.1007/s43152-024-00055-4 · Cited by 33

Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy

Mei, J., Liu, X., Tian, H., Chen, Y., Cao, Y., Zeng, J., Liu, Y., Chen, Y., Gao, Y., Yin, J., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1656 · Cited by 34

Advances in CAR-NK cell therapy for hematological malignancies

Yang, R., Yang, Y., Liu, R., Wang, Y., Yang, R., & He, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1414264 · Cited by 38

Classification of anticancer drugs: an update with FDA- and EMA-approved drugs

Ostios-García, L., Martínez-Pérez, D., Castelo, B., Herradón, N. H., Zamora, P. M., Feliú, J., & Espinosa, E. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10188-5 · Cited by 37

Engineered Cellular Vesicles Displaying Glycosylated Nanobodies for Cancer Immunotherapy

Wu, J., Lu, H., Xu, X., Rao, L., & Ge, Y. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202404889 · Cited by 34

MDSC: a new potential breakthrough in CAR-T therapy for solid tumors

Abdalsalam, N. M. F., Ibrahim, A., Saliu, M. A., Liu, T., Wan, X., & Yan, D. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01995-y · Cited by 35

A comprehensive review on targeting diverse immune cells for anticancer therapy: Beyond immune checkpoint inhibitors

Liu, D., Liu, L., Zhao, X., Zhang, X., Chen, X., Che, X., & Wu, G. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104702 · Cited by 40

Advancing gene editing therapeutics: Clinical trials and innovative delivery systems across diverse diseases

Raigani, M., Eftekhari, Z., Adeli, A., & Kazemi‐Lomedasht, F. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102666 · Cited by 36

Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy

Frlic, T., & Pavlin, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1688995 · Cited by 38

Molecular Design, Optimization, and Genomic Integration of Chimeric B Cell Receptors in Murine B Cells

Pesch, T., Bonati, L., Kelton, W., Parola, C., Ehling, R. A., Csepregi, L., Kitamura, D., & Reddy, S. T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02630 · Cited by 33

High Frequency Production of T Cell-Derived iPSC Clones Capable of Generating Potent Cytotoxic T Cells

Nagano, S., Maeda, T., Ichise, H., Kashima, S., Ohtaka, M., Nakanishi, M., Kitawaki, T., Kadowaki, N., Takaori‐Kondo, A., Masuda, K., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.006 · Cited by 33

Novel immunotherapy strategies for treatment of neuroendocrine neoplasms

Al‐Toubah, T., Cives, M., & Strosberg, J. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.12.18 · Cited by 33

Minicircle DNA-Mediated CAR T Cells Targeting CD44 Suppressed Hepatocellular Carcinoma Both in vitro and in vivo

Wang, H., Ye, X., Ju, Y., Cai, Z., Wang, X., Du, P., Zhang, M., Li, Y., & Cai, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s247836 · Cited by 33

Recent developments in cancer research: Expectations for a new remedy

Ando, K., Hu, Q., Kasagi, Y., Oki, E., & Mori, M. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12440 · Cited by 33

A single-chain antibody generation system yielding CAR-T cells with superior antitumor function

Ochi, T., Maruta, M., Tanimoto, K., Kondo, F., Yamamoto, T., Kurata, M., Fujiwara, H., Masumoto, J., Takenaka, K., & Yasukawa, M. (2021) · Communications Biology · doi:10.1038/s42003-021-01791-1 · Cited by 33

Matrix biophysical cues direct mesenchymal stromal cell functions in immunity

Wong, S. W., Lenzini, S. B., Giovanni, R., Clark-Knowles, K. V., & Shin, J. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.07.075 · Cited by 34

Identification of the Real Hub Gene and Construction of a Novel Prognostic Signature for Pancreatic Adenocarcinoma Based on the Weighted Gene Co-expression Network Analysis and Least Absolute Shrinkage and Selection Operator Algorithms

Yuan, Q., Ren, J., Wang, Z., Li, J., Deng, D., & Shang, D. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.692953 · Cited by 33

Mini-review: The market growth of diagnostic and therapeutic monoclonal antibodies – SARS CoV-2 as an example

Abd, Y. S. E., Tabll, A. A., Smolić, R., & Smolić, M. (2021) · Human Antibodies · doi:10.3233/hab-211513 · Cited by 35

Human Tumor Targeted Cytotoxic Mast Cells for Cancer Immunotherapy

Fereydouni, M., Ahani, E., Desai, P., Motaghed, M., Dellinger, A. L., Metcalfe, D. D., Yin, Y., Lee, S. H., Kafri, T., Bhatt, A. P., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871390 · Cited by 33

Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy

Ababneh, H., Abramson, J. S., Johnson, P. C., & Patel, C. G. (2022) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2022.08.007 · Cited by 34

The new progress in cancer immunotherapy

Shimu, A. S., Wei, H.-X., Li, Q., Zheng, X., & Li, B. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00887-0 · Cited by 36

Recent Research Progress of 19F Magnetic Resonance Imaging Probes: Principle, Design, and Their Application

Mo, Y., Huang, C., Liu, C., Duan, Z., Liu, J., & Wu, D. (2022) · Macromolecular Rapid Communications · doi:10.1002/marc.202200744 · Cited by 35

Advances in CAR-T Cell Therapy in Head and Neck Squamous Cell Carcinoma

Wang, H., Fu, R., Man, Q., Yang, G., Liu, B., & Bu, L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062173 · Cited by 37

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma

Aujla, A. S., Aujla, R., & Liu, D. (2019) · Biomarker Research · doi:10.1186/s40364-019-0160-4 · Cited by 33

Biomechanics of T Cell Dysfunctions in Chronic Diseases

Gunasinghe, S. D., Peres, N. G., Goyette, J., & Gaus, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.600829 · Cited by 33

The Effectiveness of Various Chemotherapeutic Agents in Cancer Treatment

Fathima, J. K., LAVANYA, V. A., Jamal, S., & Ahmed, N. (2022) · Current Pharmacology Reports · doi:10.1007/s40495-022-00289-6 · Cited by 33

Expanding CAR-T cell immunotherapy horizons through microfluidics

Kim, H., Kim, S., Lim, H., & Chung, A. J. (2024) · Lab on a Chip · doi:10.1039/d3lc00622k · Cited by 34

Amphiphilic Block Copolymer Nanostructures as a Tunable Delivery Platform: Perspective and Framework for the Future Drug Product Development

Sinsinbar, G., Bindra, A. K., Liu, S., Chia, T. W., Eng, E. C. Y., Loo, S. Y., Lam, J. H., Schultheis, K., & Nallani, M. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.3c00858 · Cited by 34

Single-domain antibodies as therapeutics for solid tumor treatment

Wang, M., Ying, T., & Wu, Y. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.016 · Cited by 33

T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer

Palecki, J., Bhasin, A., Bernstein, A., Mille, P. J., Tester, W. J., Kelly, W. K., & Zarrabi, K. K. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2356820 · Cited by 32

CAR T-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma

Tian, M., Wei, J. S., Cheuk, A., Milewski, D., Zhang, Z., Kim, Y. Y., Chou, H.-C., Liu, C., Badr, S., Pope, E. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50251-x · Cited by 33

Engineering of a Multi‐Modular DNA Nanodevice for Spatioselective Imaging and Evaluation of NK Cell‐Mediated Cancer Immunotherapy

Chen, Z., Zeng, W., Lei, Y., Liang, W., Yang, X., Yuan, R., Yang, C. J., & Zhuo, Y. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202414064 · Cited by 32

New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies

Yang, Y., Peng, H., Wang, J., & Li, F. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00573-9 · Cited by 37

Harnessing myeloid cells in cancer

Park, S., Pylaeva, E., Bhuria, V., Gambardella, A. R., Schiavoni, G., Mougiakakos, D., Kim, S.-H., & Jabłońska, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02249-2 · Cited by 35

Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility

Gupta, D., & Shaz, B. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06400-x · Cited by 32

Circulating biomarkers predictive of tumor response to cancer immunotherapy

Lee, E. Y., & Kulkarni, R. P. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1659728 · Cited by 33

Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches

Marshall, C. H., & Antonarakis, E. S. (2020) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100164 · Cited by 31

NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies

Shimizu, K., Iyoda, T., Yamasaki, S., Kadowaki, N., Tojo, A., & Fujii, S. (2020) · Cancers · doi:10.3390/cancers12040817 · Cited by 34

Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit

Luo, X., Cui, H., Cai, L., Zhu, W., Yang, W.-C., Patrick, M., Zhu, S., Huang, J., Yao, X., Yao, Y., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00623 · Cited by 32

Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation

Kamakura, D., Asano, R., Kawai, H., & Yasunaga, M. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02667-9 · Cited by 33

The Application of CAR-T Cells in Haematological Malignancies

Skórka, K., Ostapińska, K., Malesa, A., & Giannopoulos, K. (2020) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-020-00599-x · Cited by 34

Considerations for setting occupational exposure limits for novel pharmaceutical modalities

Graham, J. C., Hillegass, J., & Schulze, G. E. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2020.104813 · Cited by 32

Label-free inertial-ferrohydrodynamic cell separation with high throughput and resolution

Liu, Y., Zhao, W., Cheng, R., Puig, A., Hodgson, J., Egan, M., Pope, C. N. C., Nikolinakos, P. G., & Mao, L. (2021) · Lab on a Chip · doi:10.1039/d1lc00282a · Cited by 32

Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo

Liu, G., Zhang, Q., Liu, G., Li, D., Zhang, L., Gu, Z., Tian, H., Zhang, Y., & Tian, X. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112886 · Cited by 32

CRISPR-Cas Technology: Emerging Applications in Clinical Microbiology and Infectious Diseases

Serajian, S., Ahmadpour, E., Oliveira, S. M. R., Pereira, M. D. L., & Heidarzadeh, S. (2021) · Pharmaceuticals · doi:10.3390/ph14111171 · Cited by 35

Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review

Efficace, F., Cannella, L., Sparano, F., Giesinger, J. M., Vignetti, M., Baron, F., Bruera, E. D., Luppi, M., & Platzbecker, U. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000802 · Cited by 34

IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML

Perriello, V. M., Rotiroti, M. C., Pisani, I., Galimberti, S., Alberti, G., Pianigiani, G., Ciaurro, V., Marra, A., Sabino, M., Tini, V., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008762 · Cited by 34

Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain

Buonato, J. M., Edwards, J. P., Zaritskaya, L., Witter, A. R., Gupta, A., LaFleur, D. W., Tice, D. A., Richman, L. K., & Hilbert, D. M. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0552 · Cited by 32

Biomaterial-assisted photoimmunotherapy for synergistic suppression of cancer progression

Li, Y., Cui, J., Li, C., Deng, C., Deng, G., Zhang, H., & An, F. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108180 · Cited by 31

Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening

Ramos, A., Koch, C. E., Liu-Lupo, Y., Hellinger, R. D., Kyung, T., Abbott, K. L., Fröse, J., Goulet, D. R., Gordon, K. S., Eidell, K. P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43790-2 · Cited by 32

mRNA‐based chimeric antigen receptor T cell therapy: Basic principles, recent advances and future directions

Xiao, K., Lai, Y., Yuan, W., Li, S., Liu, X., Xiao, Z., & Xiao, H. (2023) · Interdisciplinary medicine · doi:10.1002/inmd.20230036 · Cited by 36

Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy

Hou, Y., Žák, J., Shi, Y., Pratumchai, I., Dinner, B., Wang, W., Qin, K., Weber, E. W., Teijaro, J. R., & Wu, P. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0089 · Cited by 33

A tumor-on-a-chip for in vitro study of CAR-T cell immunotherapy in solid tumors

Liu, H., Noguera-Ortega, E., Dong, X., Lee, W. D., Chang, J., Aday, S., Li, Y., Shin, Y., Shi, X., Liousia, M., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02845-z · Cited by 41

Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir

Liu, B., Zhang, W., & Zhang, H. (2019) · Current Opinion in Virology · doi:10.1016/j.coviro.2019.04.004 · Cited by 30

T-cell-receptor cross-recognition and strategies to select safe T-cell receptors for clinical translation

Bentzen, A. K., & Hadrup, S. R. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.06.003 · Cited by 31

Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome

Ye, W., Li, C. V., Bian, H., Qian, W., Jin, K., Xu, T., Guo, X., Lu, X., & Su, F. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01301-7 · Cited by 33

Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells

Russkamp, N. F., Myburgh, R., Kiefer, J. D., Neri, D., & Manz, M. G. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.01.003 · Cited by 32

Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells

Wang, H., Wang, L., Li, Y., Li, G., Zhang, X., Jiang, D., Zhang, Y.-T. Y., Liu, L., Chu, Y., & Xu, G. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02151-z · Cited by 31

Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers

McFadden, M., Singh, S. K., Oprea‐Ilies, G., & Singh, R. (2021) · Cancers · doi:10.3390/cancers13215480 · Cited by 32

Advances in Nanotechnology Development to Overcome Current Roadblocks in CAR-T Therapy for Solid Tumors

Mi, J., Ye, Q., & Min, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.849759 · Cited by 32

Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation

McComb, S., Nguyen, T., Shepherd, A., Henry, K. A., Bloemberg, D., Marcil, A., MacLean, S., Zafer, A., Gilbert, R., Gadoury, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864868 · Cited by 31

Biomarker-driven feedback control of synthetic biology systems for next-generation personalized medicine

Stefanov, B., & Fussenegger, M. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.986210 · Cited by 31

“Trojan horse” nanoparticle-delivered cancer cell membrane vaccines to enhance cancer immunotherapy by overcoming immune-escape

Wang, J., Sun, B. F., Sun, L., Niu, X., Li, L., & Xu, Z. P. (2022) · Biomaterials Science · doi:10.1039/d2bm01432g · Cited by 31

Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?

Drougkas, K., Karampinos, K. I., Karavolias, I., Koumprentziotis, I., Ploumaki, I., Triantafyllou, E., Trontzas, I. P., & Kotteas, E. A. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04547-4 · Cited by 30

DNA Nanomaterials‐Based Platforms for Cancer Immunotherapy

Tian, R., Shang, Y., Wang, Y., Jiang, Q., & Ding, B. (2023) · Small Methods · doi:10.1002/smtd.202201518 · Cited by 32

Serpin B9 controls tumor cell killing by CAR T cells

Kimman, T., Slomp, A., Martens, A. W. J., Grabherr, S., Li, S., van Diest, E., Meeldijk, J., Kuball, J. H. E., Minnema, M. C., Eldering, E., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006364 · Cited by 31

AAV-mediated delivery of a Sleeping Beauty transposon and an mRNA-encoded transposase for the engineering of therapeutic immune cells

Ye, L., Lam, S. Z., Yang, L., Suzuki, K., Zou, Y., Lin, Q., Zhang, Y., Clark, P. R., Peng, L., & Chen, S. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01058-6 · Cited by 34

Targeted Nanocarriers Co-Opting Pulmonary Intravascular Leukocytes for Drug Delivery to the Injured Brain

Nong, J., Glassman, P. M., Myerson, J. W., Zuluaga‐Ramirez, V., Rodríguez-García, A., Mukalel, A. J., Omo‐Lamai, S., Walsh, L. R., Zamora, M. E., Gong, X., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c08275 · Cited by 34

Immunotherapy for hepatocellular carcinoma

Wang, X., & Lu, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003060 · Cited by 30

CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside

Zhu, X., Xue, J., Jiang, H., & Xue, D. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02151-3 · Cited by 31

Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies

Han, X. N., & Vesely, M. D. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.07.003 · Cited by 30

Novel therapeutic targets in autoimmune hepatitis

Taubert, R., Hupa‐Breier, K. L., Jaeckel, E., & Manns, M. P. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.10.022 · Cited by 30

Noninvasive imaging in cancer immunotherapy: The way to precision medicine

Du, Y., Qi, Y., Jin, Z., & Tian, J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.08.009 · Cited by 30

Engineering Living Bacteria for Cancer Therapy

Rong, L., Lei, Q., & Zhang, X. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01286 · Cited by 30

The Microbiome and Its Implications in Cancer Immunotherapy

Choudhry, H. (2021) · Molecules · doi:10.3390/molecules26010206 · Cited by 31

Reference standards for accurate validation and optimization of assays that determine integrated lentiviral vector copy number in transduced cells

Paugh, B. S., Baranyi, L., Roy, A. J., He, H., Harris, L. N., Cole, K. D., Artlip, M., Raimund, C., Langan, P. S., Jana, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-79698-w · Cited by 29

Perfect adaptation of CD8 + T cell responses to constant antigen input over a wide range of affinities is overcome by costimulation

Trendel, N., Krüger, P., Gaglione, S. A., Nguyen, J., Pettmann, J., Sontag, E. D., & Dushek, O. (2021) · Science Signaling · doi:10.1126/scisignal.aay9363 · Cited by 33

CRASH-IT Switch Enables Reversible and Dose-Dependent Control of TCR and CAR T-cell Function

Sahillioğlu, A. C., Toebes, M., Apriamashvili, G., Gomez, R., & Schumacher, T. N. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0095 · Cited by 32

Nanoparticles Targeting Innate Immune Cells in Tumor Microenvironment

Jang, H., Kim, E. H., Chi, S.-G., Kim, S. H., & Yang, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810009 · Cited by 33

Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics

Guerra, E., Pietro, R. D., Basile, M., Trerotola, M., & Alberti, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010405 · Cited by 30

Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance

Kim, H., Choi, J., & Lee, K. (2022) · Biomedicines · doi:10.3390/biomedicines10051130 · Cited by 30

GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies

Zhang, X., Wang, T., Zhu, X., Lu, Y., Li, M., Huang, Z., Han, D., Zhang, L., Wu, Y., Li, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1103695 · Cited by 30

4-1BB-Based CAR T Cells Effectively Reverse Exhaustion and Enhance the Anti-Tumor Immune Response through Autocrine PD-L1 scFv Antibody

Cheng, K., Feng, X., Chai, Z., Wang, Z., Liu, Z., Yan, Z., Wang, Y., & Zhang, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044197 · Cited by 29

Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures

Majumder, A. (2023) · Cancers · doi:10.3390/cancers16010039 · Cited by 35

Lymph-directed immunotherapy – Harnessing endogenous lymphatic distribution pathways for enhanced therapeutic outcomes in cancer

Feeney, O. M., Gracia, G., Brundel, D. H. S., Trevaskis, N. L., Cao, E., Kaminskas, L. M., & Porter, C. J. H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.002 · Cited by 31

A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies

Wang, K., Liu, Y., Li, J., Wang, B., Bishop, R., White, C., Das, A., Levine, A. D., Ho, L., Levine, B. L., et al. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.07.002 · Cited by 29

Genetically Stable and Scalable Nanoengineering of Human Primary T Cells via Cell Mechanoporation

Hur, J., Kim, H., Kim, U., Kim, G.-B., Kim, J.-H., Joo, B., Cho, D., Lee, D.-S., & Chung, A. J. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c01720 · Cited by 28

Tandem CAR-T cells targeting MUC1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer

Wang, A., Lv, T., & Song, Y. (2023) · Cellular Immunology · doi:10.1016/j.cellimm.2023.104760 · Cited by 29

Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design

Li, Y.-R., Ochoa, C. J., Zhu, Y., Kramer, A. B., Wilson, M., Fang, Y., Chen, Y., Singh, T., DiBernardo, G., Zhu, E., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107952 · Cited by 31

CD3ζ ITAMs enable ligand discrimination and antagonism by inhibiting TCR signaling in response to low-affinity peptides

Gaud, G., Achar, S. R., Bourassa, F. X. P., Davies, J., Hatzihristidis, T., Choi, S., Kondo, T., Gossa, S., Lee, J., Juneau, P. L., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01663-2 · Cited by 32

Theranostic Uses of the Heme Pathway in Neuro-Oncology: Protoporphyrin IX (PpIX) and Its Journey from Photodynamic Therapy (PDT) through Photodynamic Diagnosis (PDD) to Sonodynamic Therapy (SDT)

Marcus, S. L., & de Souza, M. P. (2024) · Cancers · doi:10.3390/cancers16040740 · Cited by 29

Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments

Nix, M. A., & Wiita, A. P. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.02.024 · Cited by 30

Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity

Cao, J. W., Lake, J. A., Impastato, R. A., Chow, L., Perez, L., Chubb, L. S., Kurihara, J. N., Verneris, M. R., & DOW, S. W. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03642-4 · Cited by 30

Trial Watch: Adoptive cell transfer for oncological indications

Aranda, F., Buqué, A., Bloy, N., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1046673 · Cited by 33

Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

Barrett, D. M., Grupp, S. A., & June, C. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500751 · Cited by 182

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

Lundh, S. M., Jung, I.-Y., Dimitri, A. J., Vora, A., Melenhorst, J. J., Jadlowsky, J. K., & Fraietta, J. A. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00628-1 · Cited by 10

Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications

Han, Z., Ma, X., & Ma, G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28098 · Cited by 3

Abstract KN01: Updates on engineered T cells as cancer therapies

June, C. H. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-kn01